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Primary immunodeficiencies with selective susceptibility to EBV infection are rare 
conditions associated with severe lymphoproliferation. We followed a patient, son of 
consanguineous parents, referred to our center for recurrent periodic episodes of fever 
associated with tonsillitis and adenitis started after an infectious mononucleosis and 
responsive to oral steroid. An initial diagnosis of periodic fever, aphthous stomatitis, 
pharyngitis, cervical adenitis syndrome was done. In the following months, recurrent 
respiratory infections and episodes of keratitis were also observed, together with a 
progressive reduction of immunoglobulin levels and an increase of CD20+ cells. Cell 
sorting and EBV PCR showed 25,000 copies for 100,000 leukocytes with predominant 
infection of B lymphocytes. Lymph node’s biopsy revealed reactive lymphadenopathy 
with paracortical involvement consistent with a chronic EBV infection. Molecular analy-
sis of XIAP, SHA2D1A, ITK, and CD27 genes did not detect any pathogenic mutation. 
The patients underwent repeated courses of anti-CD20 therapy with only a partial 
control of the disease, followed by stem cell transplantation with a complete normal-
ization of clinical and immunological features. Whole exome sequencing of the trio 
was performed. Among the variants identified, a novel loss of function homozygous c. 
163-2A>G mutation of the CD70 gene, affecting the exon 2 AG-acceptor splice site, 
fit the expected recessive model of inheritance. Indeed, deficiency of both CD27, and, 
more recently, of its ligand CD70, has been reported as a cause of EBV-driven lymph-
oproliferation and hypogammaglobulinemia. Cell surface analysis of patient-derived 
PHA-T cell blasts and EBV-transformed lymphoblastoid cell lines confirmed absence 
of CD70 expression. In conclusion, we describe a case of severe chronic EBV infection 
caused by a novel mutation of CD70 presenting with recurrent periodic fever.
Keywords: CD70 deficiency, periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome, periodic 
fever, ebstein–Barr virus, hematopoietic stem cell transplantation
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A number of different conditions are associated with the chronic 
activation of an EBV infection. Chronic active EBV (CABEV) 
was first described in 1975 (1), to describe a condition character-
ized by the presence of chronic symptoms of EBV infection in 
the absence of malignancy, autoimmunity, or a known immuno-
deficiency (2–4). This condition is heterogeneous from both the 
clinical and immunological point of view: in fact, while in some 
patients, EBV is nearly only detected in T or NK  cells [more 
frequently in the Asian population (1–4)], in other patients, it 
is mostly detected in B cells [more common in the Caucasian 
population (5)].
However, during the past years, it became evident that a 
relevant proportion of chronic EBV infections were secondary 
to genetic defects leading to a selective susceptibility to EBV-
induced diseases. X-linked diseases caused by mutations in 
SH2D1A (6) (XLP), XIAP (7), and MAGT1 (8) or autosomal 
recessive diseases caused by mutation in ITK (9), CORO1A (10), 
and FCGR3A (11) are such an example. In this condition, patients 
develop various degrees of lymphoproliferation and immunode-
ficiency, with hemophagocytic lymphohistiocytosis, hypogam-
maglobulinemia, and/or lymphoid malignancy secondary to 
chronic EBV infection as part of the clinical picture. Biallelic 
mutations of CD27, a tumor necrosis factor (TNF) receptor 
superfamily member expressed on cells of adaptive immunity and 
NK cells cause an EBV-associate lymphoproliferative disease with 
hypogammaglobulinemia (12–14). More recently, an autosomal 
recessive deficiency of CD70, the ligand of CD27, has been associ-
ated to a combined immunodeficiency with EBV-induced B-cell 
malignancy in humans (15, 16).
Though presenting with a wide heterogeneity, most of 
the patients with chronic EBV infection share severe clinical 
manifestations with early onset and poor prognosis: common 
immunosuppressive and antiviral therapies are usually not 
effective, and most of the patients not treated with bone mar-
row transplantation die due to lymphoid malignancies (5). 
Here, we describe the genetic characterization of a patient 
with a severe chronic EBV infection due to a novel mutation of 
CD70, whose initial clinical picture resembled a periodic fever 
syndrome.
The patient, born to consanguineous parents, presented at 
the age of 15 months with a not-complicated infectious mono-
nucleosis followed by the onset of recurrent episodes of fever 
associated with exudative tonsillitis, adenitis, splenomegaly, 
and sweating, lasting 3–5 days and treated with NSAIDS or, in 
some occasions, with antibiotics. Blood examination revealed 
neutrophilic leukocytosis and elevation of acute phase reactants, 
while serum immunoglobulins were within the normal range. 
An autoinflammatory condition, consistent with periodic fever, 
aphthosis stomatitis, pharyngitis, cervical adenitis (PFAPA) 
syndrome was suspected and on-demand steroidal treatment was 
suggested with a prompt response. In the following months, the 
child continued to present periodic fever episodes with a more 
clear association with respiratory viral and bacterial infections 
and more frequent use of antibiotics. Three episodes of anterior 
uveitis were also observed. The patient presented several destruc-
tive dental caries (Figure 1A) and hyper sensibility to mosquitoes’ 
bites was reported.
At the age of 3, immunologic tests revealed a reduction in the 
level of serum immunoglobulins and a reduction of both T (in 
particular CD3+CD8+ cells) and B lymphocytes populations 
(Table 1). Quantitative PCR for EBV DNA revealed 21,935 copies 
for 100,000 leukocytes with prevalence of infection in the B cells 
(Table 2). Whole body positron emission tomography revealed 
a retroperitoneal formation of about 35 mm with an increased 
metabolism. At biopsy, staining was compatible with reactive 
lymphadenopathy with paracortical involvement associated with 
EBV infection (Figure 1B). No signs of lymphoma were observed. 
The cytofluorimetric characterization of the immunophenotype 
enlightened the presence of a mixed lymphocyte population 
composed of polyclonal T and B lymphocytes.
Most common genetic conditions possibly associated with 
chronic EBV infection and hypogammaglobulinemia were 
ruled out by molecular analysis of the coding sequence of target 
genes (SHA2D1A, XIAP, BAFF-R, and ICOS). In addition, the 
cytofluorimetric analysis of perforin, CD107, and 2B4 receptor 
was normal (data not shown). In light of these findings, a severe 
chronic EBV infection was suspected.
Taking into consideration, the overall satisfactory general 
conditions and in light of the prevalent involvement of CD20+ 
lymphocytes, after informed consent approved by G. Gaslini ethi-
cal board, treatment with rituximab (375 mg/m2/dose) was started 
with a good clinical response and a dramatic reduction of viral load 
(Figure 1C). The patient was followed longitudinally with the indi-
cation to repeat rituximab whenever the viral load exceeded 20,000 
copies/100,000 lymphomonocytic cells and/or the re-appearance 
of fever and other manifestations associated with EBV. During the 
following 2  years, the patient received only two administrations 
of rituximab, in association with i.v. immunoglobulin substitutive 
treatment every 6 weeks. The patient presented a general wellbeing 
with a regular growth, without severe infections, and with persistent 
control of the viral load and of the number of CD20 cells (Figure 1C). 
However, 3  years after the diagnosis a clear progression of the 
taBle 1 | lymphocytes population detected in the patient.
lymphocytes’ population percentage of lymphocytes 
(absolute count/mmc)
CD3+ 76 % (4071)
CD3+ CD4+ 42.5 % (2246)
CD3+ CD8+ 26.2 % (134)
CD19+ 15.4 % (814)
CD20+ 15 % (800)
CD3– CD16+ CD56+ 7 % (370)
taBle 2 | EBV DNA quantitative PCR in different lymphocytes populations.
lymphocytes’ 
population
eBV DNa quantitative pCR % of infected cells
CD3+ CD8+ 8100 copies / 1812200 cells 0.4 %
CD3+ CD4+ 10700 copies / 4584300 cells 0.2 %
CD3– CD16+ CD56+ 1700 copies / 367000 cells 0.5 %
CD19+ 386540 copies / 4500000 cells 8.6 %
FIguRe 1 | (a) Multiple caries in CD70 deficient patient. (B) Histologic analysis of patient’s lymph node showing follicular hyperplasia with paracortical expansion 
(top left), germinal centers with normal appearance (top right), follicular lysis (lower panels). (C) Copies of EBV DNA (above) and number of CD20 cells (below) 
detected in the patient. Arrows represent the infusions of rituximab. (D) Family pedigree with the c.163-2A>G variant of the CD70 gene, heterozygous in carriers, 
and homozygous in the patient. (e) CD70 genomic region and cDNA sequence of the first 3 exons in the patient is depicted, revealing the exon 2 skipping in the 
electropherogram at the bottom.
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disease was observed, with subsequent elevations of the viral load 
and an increase in the frequency and severity of respiratory tract 
infections requiring, in some cases, prolonged hospitalization. In 
this period, the patient received three consecutive administrations 
of rituximab, with only a transient clinical response. On these bases, 
hematopoietic stem cell transplantation (HSCT) was planned.
The conditioning regimen consisted of Thiotepa (8  mg/kg, 
day −7), Fludarabine (40 mg/m2/day, from day −6 to day −3), 
and Treosulfan (14  gr/m2 from day −6 to day −4). Rabbit 
anti-thymocyte globulin (ATG, 30 mg/kg from day −4 to −2), 
micophenolyc acid (30  mg/kg from day 0), and cyclosporine 
(1 mg/kg until day −2 and 3 mg/kg from day −1) were adminis-
tered as Graft-versus-Host Disease (GvHD) prophylaxis, whereas 
a single dose of rituximab (200 mg/sqm) was administered on day 
0 for prevention of EBV-related lymphoprolipherative disease.
A total of 2.88 × 108/kg mononuclear bone marrow cells were 
infused from an 8/10, EBV positive HLA-matched unrelated 
female donor (1 antigenic HLA-C mismatch in host-versus-graft 
direction, 1 bidirectional HLA-DQB1 mismatch). Neutrophils 
and platelets engraftment occurred on day +24 and +18 after 
HSCT, respectively. At first evaluation, chimerism analysis 
revealed a mixed pattern (88% donor cell), shown to be of full 
donor origin, which persisted at all subsequent evaluations. The 
early post-transplant phase was complicated by mild mucositis, 
multiple CMV reactivations successfully treated by Foscarnet 
and/or Gancyclovir, grade 2 acute GvHD (grade 2) responsive to 
FIguRe 2 | CD70 expression. (a) FACS histograms showing CD70 expression detected with anti-CD70 antibody on PHA-stimulated CD3+ T cell blasts from 
patient (Pt) or healthy donor (Ctrl), at day 7 and 23 of culture. (B) FACS histograms showing CD70 expression on lymphoblastoid cell lines derived from the Pt or 
three healthy donors (Ctrl1, Ctrl2, and Ctrl3) detected with anti-CD70 antibody. (C) FACS histograms showing CD70 expression on PHA-stimulated CD3+CD4+ 
T cell blasts from Pt pre-HSCT (red line), Pt post-HSCT (black line), or healthy donor (dashed gray line), at day 12 of culture.
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corticosteroids. Immunosuppression was progressively tapered 
and eventually discontinued 16 months after HSCT in the absence 
of any manifestation of chronic GvHD. Blood EBV DNA never 
positivized after HSCT, and specific antibodies were detected since 
month +9. After 2  years and 6  months from HSCT, the patient 
persists in good health in the absence of any sign of the disease.
Having excluded some of the most common genetic causes 
of genetic susceptibility to EBV infections, and in light of the 
severity of the clinical picture, and the consanguinity of the 
parents (Figure 1D), a whole exome sequencing (WES) approach 
was undertaken in the patients and their parents. Variants were 
prioritized with a custom pipeline to identify the genetic cause of 
patient’s condition. In particular, only variants either unreported or 
already reported in the general population with a frequency lower 
than 1% were considered. Moreover, synonymous, intronic, and 
UTR variants were excluded, in addition to splicing variants not 
specifically affecting the donor and acceptor splice sites. Among the 
homozygous variants, thus identified (Table S1 in Supplementary 
Material), a splicing variant of the CD70 gene, fitting the expected 
recessive model of inheritance, with the parents being heterozygous 
for the same mutation (Figure 1D), was further investigated. In 
particular, the variant c.163-2A>G affects the exon 2AG-acceptor 
splice site of the CD70 gene (NM_001252). To analyze the effect of 
the mutation on the transcription of the gene, we sequenced the 
complementary DNA, revealing the skipping of exon 2 (Figure 1E).
Flow cytometry analysis of CD70 expression of patient’s 
PHA-T cell blasts at 7 and 23 days of stimulation failed to detect 
even low amounts of CD70 protein. In contrast, expression of 
CD70 was detected on a fraction of PHA-stimulated T cells from 
healthy donors (Figure 2A). Similarly, CD70 was not detected on 
EBV-trasformed lymphoblastoid cells lines (EBV-LCL) derived 
from the patient, in contrast to EBV-LCL from healthy donors 
that expressed high levels of CD70 on their surface (Figure 2B). 
After HSCT, the expression of CD70 in patient’s PHA-T cell blasts 
at 12 days of culture was comparable to healthy donor (Figure 2C). 
These data demonstrate that c.163-2A>G mutation causes exon 
skipping and absence of CD70 protein expression in patient’s cells.
CD70 is the ligand of the TNF superfamily member CD27 and 
is expressed by antigen-presenting cells upon triggering of CD40 
and toll-like receptors (TLR), by T  cells upon TCR activation, 
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CD28 cross-linking, and cytokine exposure, and constitutively 
by thymic epithelial cells (17). CD27–CD70 binding provides a 
costimulatory signal for CD4 and CD8 activation (18, 19), and 
studies in mice have provided evidences for its role in memory 
expansion and protection upon reinfection (20, 21). Inborn 
errors of CD27 are a well-known cause of persistent symptomatic 
EBV viremia and hypogammaglobulinemia, thus making CD70 
mutations the likely cause of our patient’s phenotype.
While our characterization of this novel immune defect 
was on-going, two groups reported the association of CD70 
mutations with combined immunodeficiency in a total of five 
patients affected by EBV-associated Hodking’s lymphoma and 
hypogammaglobulinemia (15, 16). The groups demonstrated that 
CD70 deficiency (16) causes a reduction of in  vitro-generated 
EBV-specific cytotoxic T cell activity and to a decreased expres-
sion of 2B4 and NKG2D, receptors implicated in controlling 
EBV infection, on memory CD8+ T cells, consistent with their 
impaired capability to kill EBV-infected cells (15).
Four of the five reported patients suffered by EBV-associated 
Hodgkin’s lymphoma with an onset at 2.5, 3 (two patients), 
and 17  years of age and hypogammaglobulinemia. The initial 
presentation was a severe varicella infection with pneumonia in 
one case, encephalitis of unknown cause in another one, and HL 
in the other three cases. Our patient uniquely presented with a 
subtle history of recurrent fever and inflammatory symptoms 
was similar to PFAPA syndrome. Of note, the patient reported 
by Izawa et al. following treatment for HL, also presented with 
recurrent fever and lymphoadenopathy, while P1 in Abolhassani 
et al. presented oral aphthous ulcers.
In conclusion, we report an early diagnosed case of CD70 
deficiency with an onset of periodic fever, suggesting that in 
EBV positive patients with signs of PFAPA syndrome molecular 
analysis of CD70 gene should be performed.
MateRIals aND MetHoDs
Informed Consent
Experiments and molecular genetic analysis were performed, 
following informed consent and approval by the institute review 
board. The family gave permission for publication of clinical and 
laboratory data and photographic images.
Cell Culture
Whole blood samples were collected from the patient and healthy 
donors. Peripheral blood mononuclear cells (PBMC) were iso-
lated by Ficoll-Paque density gradient from blood samples using 
standard procedures. Expansion of T cell blasts were obtained by 
incubating PBMCs for 48 h with 1 µg/ml of phytohemagglutinin 
(PHA) (Sigma-Aldrich) in RPMI supplemented with 10% FBS 
serum, 1% penicillin, and 1% streptomycin. After 2 days, PHA-
blasts were maintained in culture with 100 U/ml IL-2.
EBV-trasformed cell lines were generated from the patient and 
control healthy donors with standard technique.
lymph Node Histology
Lymph nodes from diagnostic biopsies were fixed in 4% formalin, 
paraffin embedded and sectioned for H&E staining with standard 
techniques. Images were recorded using a Zeiss Axioskop plus 
microscope mounting a digital microscopy camera AxioCam ICc5.
Flow Cytometry
Cell staining and phenotype analyses of blast T cells and cell lines 
were performed according to standard flow cytometry methods.
Expression of CD70 on PHA-T cell blasts pre- and post-HSCT 
and lymphoblastoid cell lines derived from the patient and four 
healthy donors was evaluated by flow cytometry. Anti-CD70 
PE monoclonal antibody (clone: Ki-24, isotype: mouse IgG3, k, 
BD Biosciences), PeCy7 mouse anti-human CD3 (clone: SK7, 
isotype: mouse BALB/c IgG1, k, BD Biosciences), APC mouse 
anti-human CD4 (clone: RPA-T4, isotype: mouse IgG, k, BD 
Biosciences), and PC7 mouse anti-human CD19 (clone: J3-119, 
isotype: IgG1, mouse, Beckman Coulter) were used.
Wes and sanger sequencing Validation
Molecular analysis of SHA2D1A, XIAP, BAFF-R, and ICOS genes 
was performed through Sanger sequencing in a CLIA certified 
laboratory.
Whole exome sequencing consisted of several steps. Exome 
capture was performed on genomic DNA using the Nextera Rapid 
Capture Expanded Exome Kit (Illumina Inc., San Diego, CA, USA) 
according to manufacturer instructions. The enriched libraries 
were sequenced on the Hiseq3000 instrument with 100 bp paired-
end reads. This approach achieved an 86× average coverage over 
the 62Mb of target regions sequenced, with more than 95% regions 
covered. Data analysis has been performed using an analysis 
pipeline implemented in Orione (22). Briefly, paired-end sequence 
reads were aligned to the human genome (hg19) with BWA-MEM 
[v.0.7.9a (23)]. Initial mappings were processed using the GATK 
framework [version 2.8.1 (24)], according to the GATK best prac-
tices recommendations (25, 26). Variants were classified as known 
or novel based on dbSNP146 and annotated using KGGSeq (27).
Annotations included positions in UCSC, RefGene, GENCODE 
and ENSEMBL transcripts, OMIM and ClinVar annotations, 
potential false positive signals, allele frequency in dbSNP, ESP6500, 
1000 Genome Project (release 05/2013), and ExAC, functional 
predictions for the amino acid changes according to different 
models (SIFT, Polyphen2, LRT, MutationTaster, MutationAssessor, 
and FATHMM) retrieved from dbNSFP v 2.9 (database of human 
nonsynonymous SNPs and their functional predictions) (28).
Homozygous missense and splicing mutations at ±2bp were 
taken into account and selected based on their allele frequency 
(variants unreported or reported with a frequency of <1% in the 
general population were selected). The identified CD70 variant was 
validated by Sanger sequencing both in the proband and in his par-
ents. PCR products were purified by ExoSAP-IT (GE Healthcare) 
and directly sequenced using Big Dye v1.1 and an ABI3130 auto-
mated sequencer (Applied Biosystems, Foster City, CA, USA).
CD70 transcript Characterization
Total RNA from patient’s T cells and from three-unrelated con-
trols was isolated by a commercial RNA purification kit (RNeasy 
Mini kit, Qiagen, GmbH, Germany) and 1 µg of total RNA was 
reverse transcribed by iScript cDNA synthesis kit (Bio-Rad 
Laboratories) according to the manufacturer’s protocol. DNA 
amplification followed by Sanger sequencing was carried out on 
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the cDNA, thus obtained using CD70 specific primers designed 
on exon 1 (5′- GTGATCTGCCTCGTGGTGT-3′) and exon 3 
(5′-AGGCAATGGTACAACCTTGG-3′).
etHICs stateMeNt
All subjects gave written informed consent in accordance with 
the Declaration of Helsinki. The protocol was approved by the 
Regional Ethical Committee.
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